The long Memorial Day weekend didn't slow down the US Food and Drug Administration and industry, which produced a burst of drug development news in the closing days of May. Here's your news in brief:
Regenerative medicine sponsors stole a chunk of the spotlight. Fibrocell Science Inc. reeled in a regenerative medicine advanced therapy (RMAT) designation for its recessive dystrophic epidermolysis bullosa (RDEB) gene...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?